Literature DB >> 28353284

Models of LRRK2-Associated Parkinson's Disease.

Yulan Xiong1,2,3, Ted M Dawson4,5,6,7,8, Valina L Dawson9,10,11,12,13.   

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic causes of Parkinson's disease (PD) and also one of the strongest genetic risk factors in sporadic PD. The LRRK2 protein contains a GTPase and a kinase domain and several protein-protein interaction domains. Both in vitro and in vivo assays in different model systems have provided tremendous insights into the molecular mechanisms underlying LRRK2-induced dopaminergic neurodegeneration. Among all the model systems, animal models are crucial tools to study the pathogenesis of human disease. How do the animal models recapitulate LRRK2-induced dopaminergic neuronal loss in human PD? To answer this question, this review focuses on the discussion of the animal models of LRRK2-associated PD including genetic- and viral-based models.

Entities:  

Keywords:  Animal models; LRRK2; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28353284      PMCID: PMC5535810          DOI: 10.1007/978-3-319-49969-7_9

Source DB:  PubMed          Journal:  Adv Neurobiol


  87 in total

1.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

2.  Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.

Authors:  Ravindra Boddu; Travis D Hull; Subhashini Bolisetty; Xianzhen Hu; Mark S Moehle; João Paulo Lima Daher; Ahmed Ibrahim Kamal; Reny Joseph; James F George; Anupam Agarwal; Lisa M Curtis; Andrew B West
Journal:  Hum Mol Genet       Date:  2015-04-22       Impact factor: 6.150

3.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

4.  Translation initiator EIF4G1 mutations in familial Parkinson disease.

Authors:  Marie-Christine Chartier-Harlin; Justus C Dachsel; Carles Vilariño-Güell; Sarah J Lincoln; Frédéric Leprêtre; Mary M Hulihan; Jennifer Kachergus; Austen J Milnerwood; Lucia Tapia; Mee-Sook Song; Emilie Le Rhun; Eugénie Mutez; Lydie Larvor; Aurélie Duflot; Christel Vanbesien-Mailliot; Alexandre Kreisler; Owen A Ross; Kenya Nishioka; Alexandra I Soto-Ortolaza; Stephanie A Cobb; Heather L Melrose; Bahareh Behrouz; Brett H Keeling; Justin A Bacon; Emna Hentati; Lindsey Williams; Akiko Yanagiya; Nahum Sonenberg; Paul J Lockhart; Abba C Zubair; Ryan J Uitti; Jan O Aasly; Anna Krygowska-Wajs; Grzegorz Opala; Zbigniew K Wszolek; Roberta Frigerio; Demetrius M Maraganore; David Gosal; Tim Lynch; Michael Hutchinson; Anna Rita Bentivoglio; Enza Maria Valente; William C Nichols; Nathan Pankratz; Tatiana Foroud; Rachel A Gibson; Faycal Hentati; Dennis W Dickson; Alain Destée; Matthew J Farrer
Journal:  Am J Hum Genet       Date:  2011-09-09       Impact factor: 11.025

5.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.

Authors:  João Paulo L Daher; Olga Pletnikova; Saskia Biskup; Alessandra Musso; Sandra Gellhaar; Dagmar Galter; Juan C Troncoso; Michael K Lee; Ted M Dawson; Valina L Dawson; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-02-21       Impact factor: 6.150

6.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

7.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

8.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

9.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

10.  The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.

Authors:  M Lichtenberg; A Mansilla; V R Zecchini; A Fleming; D C Rubinsztein
Journal:  Cell Death Dis       Date:  2011-08-25       Impact factor: 8.469

View more
  21 in total

Review 1.  In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  Stem Cells Dev       Date:  2018-03-29       Impact factor: 3.272

Review 2.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

3.  From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.

Authors:  Jeff S Piotrowski; Daniel F Tardiff
Journal:  Methods Mol Biol       Date:  2019

Review 4.  Dopaminergic Axons: Key Recitalists in Parkinson's Disease.

Authors:  Abhishek Kumar Mishra; Anubhuti Dixit
Journal:  Neurochem Res       Date:  2021-10-12       Impact factor: 3.996

5.  Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.

Authors:  Yulan Xiong; Stewart Neifert; Senthilkumar S Karuppagounder; Qinfang Liu; Jeannette N Stankowski; Byoung Dae Lee; Han Seok Ko; Yunjong Lee; Jonathan C Grima; Xiaobo Mao; Haisong Jiang; Sung-Ung Kang; Deborah A Swing; Lorraine Iacovitti; Lino Tessarollo; Ted M Dawson; Valina L Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

Review 6.  Modeling Parkinson's Disease in Drosophila: What Have We Learned for Dominant Traits?

Authors:  Yulan Xiong; Jianzhong Yu
Journal:  Front Neurol       Date:  2018-04-09       Impact factor: 4.003

Review 7.  The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.

Authors:  Kai-Jung Lin; Kai-Lieh Lin; Shang-Der Chen; Chia-Wei Liou; Yao-Chung Chuang; Hung-Yu Lin; Tsu-Kung Lin
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

8.  Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease.

Authors:  Lindsey M Crown; Mitchell J Bartlett; Jean-Paul L Wiegand; Allison J Eby; Emily J Monroe; Kathleen Gies; Luke Wohlford; Matthew J Fell; Torsten Falk; Stephen L Cowen
Journal:  Front Neurol       Date:  2020-05-08       Impact factor: 4.003

9.  Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration.

Authors:  Qinfang Liu; Judith Bautista-Gomez; Daniel A Higgins; Jianzhong Yu; Yulan Xiong
Journal:  Sci Signal       Date:  2021-07-27       Impact factor: 8.192

10.  Adenovirus-induced Reactive Astrogliosis Exacerbates the Pathology of Parkinson's Disease.

Authors:  Heeyoung An; Hyowon Lee; Seulkee Yang; Woojin Won; C Justin Lee; Min-Ho Nam
Journal:  Exp Neurobiol       Date:  2021-06-30       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.